Table 3 Univariable analysis of factors associated with CDI in hospitalized IBD patients according to CDI defined by the laboratory dataset or hospitalization admission and discharge database (DAD)
Laboratory dataset | DAD | |||
|---|---|---|---|---|
Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value | |
5-ASA | 1.53 (0.99–2.37) | 0.054 | 1.75 (1.14–2.68) | 0.010 |
Thiopurines | 1.30 (0.74–2.30) | 0.36 | 1.33 (0.73–2.43) | 0.36 |
Anti-TNF | 0.85 (0.38–1.91) | 0.69 | 1.51 (0.73–3.11) | 0.26 |
Corticosteroids | 2.81 (1.83–4.32) | < 0.001 | 2.45 (1.59–3.78) | < 0.001 |
Any antibiotic | 3.26 (2.10–5.05) | < 0.001 | 4.36 (2.78–6.83) | < 0.001 |
Metronidazole | 4.24 (2.20–8.17) | < 0.001 | 5.51 (2.72–11.2) | < 0.001 |
Ciprofloxacin | 2.95 (1.58–5.50) | < 0.001 | 3.73 (1.95–7.16) | < 0.001 |
Clindamycin | 5.92 (1.30–26.9) | 0.021 | 5.70 (1.51–21.5) | 0.010 |
Prior hospital admission | 3.48 (2.28–5.33) | < 0.001 | 3.81 (2.46–5.89) | < 0.001 |
Surgery | 0.97 (0.58–1.62) | 0.90 | 0.74 (0.44–1.25) | 0.26 |
Charlson Comorbidity index score | ||||
0 | Reference | Reference | ||
1 | 1.20 (0.65–2.22) | 0.57 | 1.64 (0.91–2.97) | 0.10 |
2 | 3.18 (1.69–5.98) | < 0.001 | 2.90 (1.50–5.62) | 0.002 |
3+ | 1.87 (0.94–3.75) | 0.076 | 2.57 (1.39–4.74) | 0.003 |
Ambulatory care | ||||
Lowest quartile | Reference | Reference | ||
2nd quartile | 1.82 (0.83–3.99) | 0.14 | 1.88 (0.83–4.27) | 0.13 |
3rd quartile | 4.73 (2.31–9.70) | < 0.001 | 4.84 (2.36–9.94) | < 0.001 |
Highest quartile | 5.45 (2.68–11.1) | < 0.001 | 6.69 (3.24–13.8) | < 0.001 |